Not Yet RecruitingPhase 2ACTRN12611000484943

A randomised, placebo-controlled trial of glycopyrrolate for the treatment of noisy respiratory secretions at the end of life-A pilot study


Sponsor

Dr Caitlin Sheehan

Enrollment

24 participants

Start Date

Jun 1, 2011

Study Type

Interventional

Conditions

Summary

This study looks at the effect of a drug, called Glycopyrrolate, on noisy rattling breathing in palliative care patients at the end of life. Who is it for? You can join this study if you are an inpatient in a Palliative Care unit and are willing to discuss end of life care. Trial details Participants will be randomly divided into one of two groups. One group will receive a drug called Glycopyrrolate. This is administered via an injection followed by a continuous infusion (into the vein) for a duration of 24 hours . The other group will receive a placebo (sham) treatment also delivered in the same manner. The placebo has no expected treatment effect. Participants will not know which group they have been allocated to. This study aims to determine whether a larger scale trial of the drug, Glycopyrrolate, is feasible for the treatment of noisy rattling breathing at the end of life.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This pilot trial tests whether glycopyrrolate, an anticholinergic medication, can reduce noisy respiratory secretions (sometimes called the 'death rattle') in patients at the end of life. This distressing symptom occurs when patients can no longer clear throat secretions. Eligible participants are adults 18 or older with a life-limiting illness who are inpatients in a palliative care unit.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Glycopyrrolate 0.4mg initial subcutaneous dose immediately followed by continuous subcutaneous infusion of 1.2mg/24hours ( 0.05mg/hr) for a total of 24 hours.

Glycopyrrolate 0.4mg initial subcutaneous dose immediately followed by continuous subcutaneous infusion of 1.2mg/24hours ( 0.05mg/hr) for a total of 24 hours.


Locations(1)

NSW, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000484943